C'mon, how can you trust a CEO who clearly misrepresents
not only the time-line of the German "approval" but
the actual meaning of a hospital exemption.
The Hospital Exemption for Germany says NOTHING about the drug's efficacy. All you have to do is demonstrate safety, and that the drug is individually customized (and some other junk, but NOT efficacy). It is indeed, as AF points out and NWBO filings stated for years, a compassionate use approval. If a drug is safe (causes no material harm) and a patient has no other useful options, then why shouldn't they be able to try an experimental treatment?
Doesn't mean the thing WORKS!
Put your money to work at a company which may really be a
cancer-fighting game-changer. Clearly this therapy
has minimal value, even if it exhibits some benefits in
the original smaller survey. Powers is just delaying the
inevitable (and milking investors) by expanding the trials.
IMO, of course.